Clinical Trials Logo

Clinical Trial Summary

Multicenter phase II study on trabectedin in patients advanced uterine and ovarian carcinosarcoma. Patients will receive trabectedin until disease progression or unacceptable toxicity. Disease response evaluation will be assessed every 9 weeks.

Clinical Trial Description

This is a Phase II, multi-centre, single arm study aiming at evaluating efficacy and toxicity of Trabectedin in a population of advanced or recurrent ovarian and uterine carcinosarcoma.

Trabectedin will be infused at the dose of 1.3 mg/m2 as a 3- hour iv infusion every 3 weeks via a central venous catheter. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT02993705
Study type Interventional
Source Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Status Active, not recruiting
Phase Phase 2
Start date February 22, 2017
Completion date March 2021

See also
  Status Clinical Trial Phase
Terminated NCT03509207 - Vorinostat (SAHA) in Uterine Sarcoma Phase 2